Fresh analysis reveals that people who stop using popular GLP-1 drugs like semaglutide or tirzepatide tend to recover shed pounds much more quickly than those who halt traditional diet and exercise programs.
Published data in a prominent health publication points out that while overweight individuals frequently drop about a fifth of their total mass while undergoing treatment, the mass comes back at an estimated rate of 0.8 kg per month after stopping.
"People using these treatments need to be cognizant of the danger of fast rebound weight gain when the treatment is stopped," warns lead investigator Dr. Susan Jebb.
Such speed of regain means a return to pre-treatment mass within about a year and a half.
Weighing Approaches
The research, which looked at 37 of studies involving thousands of participants, contrasted the results of GLP-1 agonists with older methods.
Scientists note that people who lose weight through diet and exercise usually see a more gradual weight regain—approximately 100 grams monthly—once they finish.
Explaining the Rapid Rebound
Doctors suggest the mode of action of the drugs is key to understanding the accelerated weight return.
GLP-1 drugs mimic a body's own chemical called GLP-1, which moderates appetite.
"Artificially providing GLP-1 concentrations far above than normal might result in the body to generate a reduced amount of its endogenous hormone, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition specialist.
"Stopping of this hormone supplement results in hunger is unsuppressed, making binge eating a significant risk."
An Ongoing Issue?
Health authorities recommend the jabs for people with obesity-related medical conditions, alongside prescribed diet and exercise modifications.
Many experts contend that, considering the significant potential of relapse, the treatment is often ongoing.
This view is echoed by drug manufacturers, who say that the findings "underscore the long-term character of excess weight," akin to managing diseases like diabetes.
Patient Testimonies
People who have come off the jabs explain a powerful resurgence of cravings.
"I experienced something flipping and you become ravenous," described one woman.
This challenge is worsened if individuals have not developed lasting lifestyle or habit changes during treatment.
Growing Interest
Survey data show that millions of adults in the UK have tried weight-loss jabs in the past year, with demand being substantial.
- Adoption is more common among women compared to males.
- The 40s and 50s demographic shows the greatest level of interest.
- Many access the medications through private healthcare rather than the NHS.
Finally, researchers emphasize that while GLP-1 drugs are effective agents for weight loss, they are not a standalone fix and long-term success likely depends on combined lifestyle support.
